sulfasalazine has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brenner, EJ | 1 |
| Pigneur, B | 1 |
| Focht, G | 1 |
| Zhang, X | 1 |
| Ungaro, RC | 1 |
| Colombel, JF | 1 |
| Turner, D | 1 |
| Kappelman, MD | 1 |
| Ruemmele, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834] | 472 participants (Actual) | Observational | 2020-05-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for sulfasalazine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co | 2021 |